Immunomodulating activity of RU 41740: in vitro and in vivo studies on human lymphocytes.
A group of institutionalized elderly subjects, selected on the basis of their skin hypoergy and displaying different kinds of T and B lymphocyte impairments has been chosen as a model to verify the in vivo immunopotentiating activity of RU 41740 on human lymphocytes. Oral treatment with the drug was able to: restore or improve the cutaneous delayed hypersensitivity to recall antigens; significantly increase the blastigenetic response to mitogenic and submitogenic doses of PHA and PWM and improve the in vitro PWM-induced synthesis of IgG and IgM. The immunopharmacological activity of RU 41740 appeared to persist three months after the end of therapy, without any direct stimulating activity on the peripheral blood lymphocytes. The in vitro results seem to suggest that peripheral lymphocytes are not directly influenced by the drug.
D000276:Adjuvants, Immunologic; D000284:Administration, Oral; D000368:Aged; D001426:Bacterial Proteins; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D006968:Hypersensitivity, Delayed; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008934:Mitogens / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D001426:Bacterial Proteins; D006023:Glycoproteins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008934:Mitogens; C037567:glycoprotein, Klebsiella pneumoniae